ALPHAMAB-B (09966) Appoints Dr. Wang Hongwei as Chief Technology Officer to Lead Process and Manufacturing Operations

Bulletin Express

Mar 11

Alphamab Oncology (ALPHAMAB-B, 09966) has named Dr. Wang Hongwei chief technology officer, according to a voluntary announcement released on 11 March 2026. Dr. Wang will oversee process development, analytical development, production and quality management across the company’s biologics portfolio.

Dr. Wang brings more than 15 years of Chemistry, Manufacturing and Controls experience, having guided six innovative biologic drugs to regulatory approval and commercialisation, and advanced over 20 additional candidates to pivotal clinical stages.

Career background: • Jiangsu Hengrui Pharmaceuticals (2011–2018): progressed from senior researcher to director of the Institute of Biologics. • Suzhou Suncadia Biopharmaceuticals, a Hengrui subsidiary (2018–2026): served as deputy general manager and subsequently general manager. • Hengrui Pharmaceuticals Biopharmaceutical Division (2023–2026): general manager, responsible for coordinating biologics development and manufacturing operations.

Academic credentials: Dr. Wang earned a bachelor’s degree in bioscience from Henan Normal University in 2006 and a Ph.D. in cell biology (immunology) from the University of Science and Technology of China in 2011. He is a member of expert panels under the PRC Ministry of Science and Technology and the Ministry of Industry and Information Technology.

The board, chaired by Dr. Xu Ting, extended its formal welcome to Dr. Wang upon his appointment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/1192614149"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192614149\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192614149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192614149","market":"us","top_or_hot":-1,"title":"ALPHAMAB-B (09966) Appoints Dr. Wang Hongwei as Chief Technology Officer to Lead Process and Manufacturing Operations","media":"Bulletin Express","content":"<p>Alphamab Oncology (ALPHAMAB-B, 09966) has named Dr. Wang Hongwei chief technology officer, according to a voluntary announcement released on 11 March 2026. Dr. Wang will oversee process development, analytical development, production and quality management across the company’s biologics portfolio.</p>\n<p>Dr. Wang brings more than 15 years of Chemistry, Manufacturing and Controls experience, having guided six innovative biologic drugs to regulatory approval and commercialisation, and advanced over 20 additional candidates to pivotal clinical stages.</p>\n<p>Career background:  \n• Jiangsu Hengrui Pharmaceuticals (2011–2018): progressed from senior researcher to director of the Institute of Biologics.  \n• Suzhou Suncadia Biopharmaceuticals, a Hengrui subsidiary (2018–2026): served as deputy general manager and subsequently general manager.  \n• Hengrui Pharmaceuticals Biopharmaceutical Division (2023–2026): general manager, responsible for coordinating biologics development and manufacturing operations.</p>\n<p>Academic credentials:  \nDr. Wang earned a bachelor’s degree in bioscience from Henan Normal University in 2006 and a Ph.D. in cell biology (immunology) from the University of Science and Technology of China in 2011. He is a member of expert panels under the PRC Ministry of Science and Technology and the Ministry of Industry and Information Technology.</p>\n<p>The board, chaired by Dr. Xu Ting, extended its formal welcome to Dr. Wang upon his appointment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALPHAMAB-B (09966) Appoints Dr. Wang Hongwei as Chief Technology Officer to Lead Process and Manufacturing Operations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALPHAMAB-B (09966) Appoints Dr. Wang Hongwei as Chief Technology Officer to Lead Process and Manufacturing Operations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-11 08:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alphamab Oncology (ALPHAMAB-B, 09966) has named Dr. Wang Hongwei chief technology officer, according to a voluntary announcement released on 11 March 2026. Dr. Wang will oversee process development, analytical development, production and quality management across the company’s biologics portfolio.</p>\n<p>Dr. Wang brings more than 15 years of Chemistry, Manufacturing and Controls experience, having guided six innovative biologic drugs to regulatory approval and commercialisation, and advanced over 20 additional candidates to pivotal clinical stages.</p>\n<p>Career background:  \n• Jiangsu Hengrui Pharmaceuticals (2011–2018): progressed from senior researcher to director of the Institute of Biologics.  \n• Suzhou Suncadia Biopharmaceuticals, a Hengrui subsidiary (2018–2026): served as deputy general manager and subsequently general manager.  \n• Hengrui Pharmaceuticals Biopharmaceutical Division (2023–2026): general manager, responsible for coordinating biologics development and manufacturing operations.</p>\n<p>Academic credentials:  \nDr. Wang earned a bachelor’s degree in bioscience from Henan Normal University in 2006 and a Ph.D. in cell biology (immunology) from the University of Science and Technology of China in 2011. He is a member of expert panels under the PRC Ministry of Science and Technology and the Ministry of Industry and Information Technology.</p>\n<p>The board, chaired by Dr. Xu Ting, extended its formal welcome to Dr. Wang upon his appointment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09966","symbol_name":"康宁杰瑞制药-B","start_time":0,"source_url":"","article_id":"1192614149","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192614149","pubTimestamp":1773188577,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Alphamab Oncology (ALPHAMAB-B, 09966) has named Dr. Wang Hongwei chief technology officer, according to a voluntary announcement released on 11 March 2026. Dr. Wang will oversee process development,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09966":"康宁杰瑞制药-B"},"translate_title":"康宁杰瑞-B(09966)任命王宏伟博士为首席技术官，领导工艺和制造运营","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":1},"content_text":"Alphamab Oncology (ALPHAMAB-B, 09966) has named Dr. Wang Hongwei chief technology officer, according to a voluntary announcement released on 11 March 2026. Dr. Wang will oversee process development, analytical development, production and quality management across the company’s biologics portfolio.\nDr. Wang brings more than 15 years of Chemistry, Manufacturing and Controls experience, having guided six innovative biologic drugs to regulatory approval and commercialisation, and advanced over 20 additional candidates to pivotal clinical stages.\nCareer background:  \n• Jiangsu Hengrui Pharmaceuticals (2011–2018): progressed from senior researcher to director of the Institute of Biologics.  \n• Suzhou Suncadia Biopharmaceuticals, a Hengrui subsidiary (2018–2026): served as deputy general manager and subsequently general manager.  \n• Hengrui Pharmaceuticals Biopharmaceutical Division (2023–2026): general manager, responsible for coordinating biologics development and manufacturing operations.\nAcademic credentials:  \nDr. Wang earned a bachelor’s degree in bioscience from Henan Normal University in 2006 and a Ph.D. in cell biology (immunology) from the University of Science and Technology of China in 2011. He is a member of expert panels under the PRC Ministry of Science and Technology and the Ministry of Industry and Information Technology.\nThe board, chaired by Dr. Xu Ting, extended its formal welcome to Dr. Wang upon his appointment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}